(Q38072259)

28 August 2017

1 reference

title

Cardiovascular effects of gliptins (English)

1 reference

28 August 2017

1 reference

André J Scheen

1

1 reference

28 August 2017

language of work or name

English

0 references

publication date

8 January 2013

1 reference

Nature Reviews Cardiology

28 August 2017

published in

1 reference

28 August 2017

volume

10

1 reference

28 August 2017

issue

2

1 reference

28 August 2017

page(s)

73-84

1 reference

Diabetes mellitus, fasting glucose, and risk of cause-specific death

28 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.183

Intensive glycaemic control for patients with type 2 diabetes: systematic review with meta-analysis and trial sequential analysis of randomised clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.183

Current management strategies for coexisting diabetes mellitus and obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.183

Diabetes and obesity: therapeutic targeting and risk reduction - a complex interplay

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.183

Cardiovascular implications of antihyperglycemic therapies for type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.183

A review of gliptins in 2011.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.183

Alogliptin: a review of its use in the management of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.183

Linagliptin: in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.183

Saxagliptin: a review of its use as combination therapy in the management of type 2 diabetes mellitus in the EU.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.183

Sitagliptin: a review of its use in the management of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.183

Vildagliptin: a review of its use in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.183

DPP-4 inhibitors in the management of type 2 diabetes: a critical review of head-to-head trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.183

Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.183

Longer term safety of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.183

Effect of antidiabetic agents added to metformin on glycaemic control, hypoglycaemia and weight change in patients with type 2 diabetes: a network meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.183

Hypoglycaemia in Type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.183

Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.183

Bodyweight changes associated with antihyperglycaemic agents in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.183

Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.183

Cardiovascular biology of the incretin system

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.183

Emerging cardiovascular actions of the incretin hormone glucagon-like peptide-1: potential therapeutic benefits beyond glycaemic control?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.183

Cardiovascular consequences of drugs used for the treatment of diabetes: potential promise of incretin-based therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.183

Clinical implications of cardiovascular preventing pleiotropic effects of dipeptidyl peptidase-4 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.183

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.183

The effect of glucagon-like peptide 1 on cardiovascular risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.183

GLP-1 receptor agonists: a clinical perspective on cardiovascular effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.183

Cardiovascular effects of the DPP-4 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.183

Inhibitor selectivity in the clinical application of dipeptidyl peptidase-4 inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.183

Dipeptidyl-peptidase IV converts intact B-type natriuretic peptide into its des-SerPro form

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.183

Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.183

Synergy between CD26/DPP-IV inhibition and G-CSF improves cardiac function after acute myocardial infarction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.183

Differential processing of substance P and neurokinin A by plasma dipeptidyl(amino)peptidase IV, aminopeptidase M and angiotensin converting enzyme.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.183

Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.183

The oral dipeptidyl peptidase-4 inhibitor sitagliptin increases circulating endothelial progenitor cells in patients with type 2 diabetes: possible role of stromal-derived factor-1alpha.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.183

Dipeptidyl peptidase-4 inhibitor improves neovascularization by increasing circulating endothelial progenitor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.183

Genetic deletion or pharmacological inhibition of dipeptidyl peptidase-4 improves cardiovascular outcomes after myocardial infarction in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.183

The myocardial infarct size-limiting effect of sitagliptin is PKA-dependent, whereas the protective effect of pioglitazone is partially dependent on PKA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.183

The potential effects of anti-diabetic medications on myocardial ischemia-reperfusion injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.183

Glucose lowering and anti-atherogenic effects of incretin-based therapies: GLP-1 analogues and DPP-4-inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.183

Dipeptydil peptidase-4 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.183

Predictors of response to dipeptidyl peptidase-4 inhibitors: evidence from randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.183

A meta-analysis of placebo-controlled clinical trials assessing the efficacy and safety of incretin-based medications in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.183

Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.183

The role of incretins in glucose homeostasis and diabetes treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.183

Robust improvements in fasting and prandial measures of beta-cell function with vildagliptin in drug-naïve patients: analysis of pooled vildagliptin monotherapy database

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.183

Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differences.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.183

Postprandial hyperglycemia/hyperlipidemia (postprandial dysmetabolism) is a cardiovascular risk factor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.183

Antidiabetic medications in overweight/obese patients with type 2 diabetes: drawbacks of current drugs and potential advantages of incretin-based treatment on body weight.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.183

Diabetes medications and body weight

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.183

Management of type 2 diabetes: new and future developments in treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.183

A review of the effects of antihyperglycaemic agents on body weight: the potential of incretin targeted therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.183

Treatment with sitagliptin or metformin does not increase body weight despite predicted reductions in urinary glucose excretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.183

Weight neutrality with the DPP-4 inhibitor, vildagliptin: mechanistic basis and clinical experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.183

Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.183

Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.183

Weight loss, glycemic control, and changes in cardiovascular biomarkers in patients with type 2 diabetes receiving incretin therapies or insulin in a large cohort database

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.183

Cardiovascular effects of antidiabetic agents: focus on blood pressure effects of incretin-based therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.183

Interactive Hemodynamic Effects of Dipeptidyl Peptidase-IV Inhibition and Angiotensin-Converting Enzyme Inhibition in Humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.183

Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on blood pressure in nondiabetic patients with mild to moderate hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.183

Dipeptidyl Peptidase IV Inhibition Alters the Hemodynamic Response to Angiotensin-Converting Enzyme Inhibition in Humans With the Metabolic Syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.183

Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.183

The role of incretins in salt-sensitive hypertension: the potential use of dipeptidyl peptidase-IV inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.183

Natriuretic effect by exendin-4, but not the DPP-4 inhibitor alogliptin, is mediated via the GLP-1 receptor and preserved in obese type 2 diabetic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.183

Effects of insulin and other antihyperglycaemic agents on lipid profiles of patients with diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.183

Postprandial hyperlipidemia, endothelial dysfunction and cardiovascular risk: focus on incretins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.183

Incretin-based therapies for treatment of postprandial dyslipidemia in insulin-resistant states

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.183

Effect of sitagliptin therapy on postprandial lipoprotein levels in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.183

Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.183

Dipeptidyl-peptidase-IV inhibition augments postprandial lipid mobilization and oxidation in type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.183

Lowering of postprandial lipids in individuals with type 2 diabetes treated with alogliptin and/or pioglitazone: a randomised double-blind placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.183

The glucagon-like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.183

DPP-4 inhibitors and lipids: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.183

Long-term dipeptidyl-peptidase 4 inhibition reduces atherosclerosis and inflammation via effects on monocyte recruitment and chemotaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.183

DPP-4 (CD26) inhibitor alogliptin inhibits atherosclerosis in diabetic apolipoprotein E-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.183

Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.183

Sitagliptin reduces albuminuria in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.183

Sitagliptin exerts an antinflammatory action

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.183

Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes: role of dipeptidyl peptidase-IV inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.183

Effects of a vildagliptin/metformin combination on markers of atherosclerosis, thrombosis, and inflammation in diabetic patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.183

The possible protective role of glucagon-like peptide 1 on endothelium during the meal and evidence for an "endothelial resistance" to glucagon-like peptide 1 in diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.183

The effect of sitagliptin versus glibenclamide on arterial stiffness, blood pressure, lipids, and inflammation in type 2 diabetes mellitus patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.183

Insulin resistance and endothelial dysfunction: the road map to cardiovascular diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.183

Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.183

Incretin-based therapies and cardiovascular risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.183

Vildagliptin improves endothelium-dependent vasodilatation in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.183

Cardiovascular effects of DPP-4 inhibition: beyond GLP-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.183

Sitagliptin: anti-platelet effect in diabetes and healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.183

DPP-4 inhibition by sitagliptin improves the myocardial response to dobutamine stress and mitigates stunning in a pilot study of patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.183

SDF-1α as a therapeutic stem cell homing factor in myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.183

Safety and efficacy of SITAgliptin plus GRanulocyte-colony-stimulating factor in patients suffering from Acute Myocardial Infarction (SITAGRAMI-Trial)--rationale, design and first interim analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.183

Dipeptidyl-peptidase IV and B-type natriuretic peptide. From bench to bedside

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.183

Glucagon-like peptide-1-based therapies and cardiovascular disease: looking beyond glycaemic control.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.183

Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.183

Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.183

Assessing the cardio-cerebrovascular safety of vildagliptin: meta-analysis of adjudicated events from a large Phase III type 2 diabetes population

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.183

A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.183

Saxagliptin for the treatment of type 2 diabetes mellitus: assessing cardiovascular data

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.183

Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.183

Ongoing clinical trials evaluating the cardiovascular safety and efficacy of therapeutic approaches to diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.183

The design and rationale of the saxagliptin assessment of vascular outcomes recorded in patients with diabetes mellitus-thrombolysis in myocardial infarction (SAVOR-TIMI) 53 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.183

EXamination of CArdiovascular OutcoMes with AlogliptIN versus Standard of CarE in Patients with Type 2 Diabetes Mellitus and Acute Coronary Syndrome (EXAMINE)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.183

Dipeptidyl peptidase-4 inhibitors and preservation of pancreatic islet-cell function: a critical appraisal of the evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.183

Dipeptidyl peptidase-4 inhibition and the treatment of type 2 diabetes: preclinical biology and mechanisms of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.183

Biology of incretins: GLP-1 and GIP

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.183

Acute DPP-4 inhibition modulates vascular tone through GLP-1 independent pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.183

A dipeptidyl peptidase-4 inhibitor, des-fluoro-sitagliptin, improves endothelial function and reduces atherosclerotic lesion formation in apolipoprotein E-deficient mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.183

The synergistic effect of valsartan and LAF237 [(S)-1-[(3-hydroxy-1-adamantyl)ammo]acetyl-2-cyanopyrrolidine] on vascular oxidative stress and inflammation in type 2 diabetic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.183

Vildagliptin blocks vascular injury in thoracic aorta of diabetic rats by suppressing advanced glycation end product-receptor axis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.183

Effects of DPP-4 inhibitors on the heart in a rat model of uremic cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.183

Pre-treatment with a DPP-4 inhibitor is infarct sparing in hearts from obese, pre-diabetic rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.183

Effects of DPP-4 inhibition on cardiac metabolism and function in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.183

Effects of sitagliptin treatment on dysmetabolism, inflammation, and oxidative stress in an animal model of type 2 diabetes (ZDF rat)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.183

Early and late effects of the DPP-4 inhibitor vildagliptin in a rat model of post-myocardial infarction heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.183

Dipeptidyl peptidase IV inhibition attenuates blood pressure rising in young spontaneously hypertensive rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.183

Dipeptidyl peptidase IV inhibition improves cardiorenal function in overpacing-induced heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.183

Dipeptidyl Peptidase 4 Inhibitor Sitagliptin Protects Endothelial Function in Hypertension Through a Glucagon–Like Peptide 1–Dependent Mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.183

Dipeptidyl peptidase-4 inhibitors and HbA1c target of <7% in type 2 diabetes: meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.183

Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.183

Dipeptidyl peptidase-4 inhibitor: another player for cardiovascular protection

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.183

Dipeptidyl(amino)peptidase IV and post proline cleaving enzyme in cultured endothelial and smooth muscle cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.183

Proteolytic processing of neuropeptide Y and peptide YY by dipeptidyl peptidase IV

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.183

DPP4 inhibition improves functional outcome after renal ischemia-reperfusion injury

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.183

Vascular protective effects of diabetes medications that mimic or increase glucagon-like peptide-1 activity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.183

Effect of glucagon-like peptide-1 (GLP-1) on glycemic control and left ventricular function in patients undergoing coronary artery bypass grafting

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.183

Reduced CD26 expression is associated with improved cardiac function after acute myocardial infarction: insights from the REPERATOR study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.183

Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.183

Incretins as a novel therapeutic strategy in patients with diabetes and heart failure.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.183

Assessing the cardiovascular safety of diabetes therapies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.183

2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.183

Glucose-independent improvement of vascular dysfunction in experimental sepsis by dipeptidyl-peptidase 4 inhibition

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.183

Cardioprotective effects of metformin and vildagliptin in adult rats with insulin resistance induced by a high-fat diet

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.183

Sitagliptin protects renal ischemia reperfusion induced renal damage in diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2012.183

Cardioprotective effect of dipeptidyl peptidase-4 inhibitor during ischemia-reperfusion injury

31 March 2020

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23296071

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Sitagliptin, a dipeptidyl peptidase-4 inhibitor, decreases systolic blood pressure in Japanese hypertensive patients with type 2 diabetes

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23296071

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Glucagon-like peptide-1 receptor agonists and cardiovascular events: a meta-analysis of randomized clinical trials

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23296071

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/NRCARDIO.2012.183

1 reference

28 August 2017

1 reference